[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352618-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352618-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","analysis-of-the-mechanism-and-prognostic-value-of-prkcq-as1-in-inhibiting-the-progression-of-lung-adenocarcinoma-via-regulating-the-pd-1pd-l1-pathway","Analysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway","","The study examines long non-coding RNA PRKCQ-AS1 in lung adenocarcinoma (LUAD), focusing on its expression pattern, clinical relevance, and molecular mechanism. Expression and prognostic associations were assessed using TCGA data and validated in patient specimens. Functional experiments in NCI-H1395 cells evaluated proliferation, migration, invasion, and apoptosis after PRKCQ-AS1 modulation. Mechanistic results show PRKCQ-AS1 is downregulated in LUAD and correlates with worse TNM stage and prognosis. Silencing PRKCQ-AS1 enhances malignant phenotypes and increases PD-1/PD-L1, indicating reduced immune escape inhibition.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/analysis-of-the-mechanism-and-prognostic-value-of-prkcq-as1-in-inhibiting-the-progression-of-lung-adenocarcinoma-via-regulating-the-pd-1pd-l1-pathway/352618/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/analysis-of-the-mechanism-and-prognostic-value-of-prkcq-as1-in-inhibiting-the-progression-of-lung-adenocarcinoma-via-regulating-the-pd-1pd-l1-pathway/352618.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was PRKCQ-AS1 expression and clinical significance evaluated in LUAD?","Question",{"text":63,"@type":64},"PRKCQ-AS1 expression levels and clinical significance were analyzed using TCGA data and validated with clinical specimens. The results linked lower PRKCQ-AS1 to advanced TNM stage and poor prognosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What impact does PRKCQ-AS1 knockdown have on LUAD cell behaviors?",{"text":68,"@type":64},"Silencing PRKCQ-AS1 significantly enhanced proliferation, migration, and invasion of LUAD cells in vitro while suppressing apoptosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism connects PRKCQ-AS1 to immune escape in LUAD?",{"text":72,"@type":64},"PRKCQ-AS1 knockdown upregulated PD-1 and PD-L1 expression. The study indicates PRKCQ-AS1 inhibits immune escape by suppressing the PD-1/PD-L1 signaling axis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352618,1790323408,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nAnalysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway  \nMeijie Wu1,3, Yufang Wang1,3, Guoding He2, Yancheng Lin2, Ben Liu1􀀍 & Yongzhi Lun1􀀍  \nTo investigate the expression profile and biological functions of long non-coding RNA PRKCQ-AS1 in lung adenocarcinoma (LUAD) and to elucidate the underlying mechanism by which PRKCQ-AS1 modulates tumor immune escape through regulation of the PD-1/PD-L1 signaling pathway. The expression levels and clinical significance of PRKCQ-AS1 in LUAD were analyzed using data from The Cancer Genome Atlas (TCGA) database and validated with clinical specimens. A competitive endogenous RNA (ceRNA) regulatory network mediated by PRKCQ-AS1 was constructed, followed by functional enrichment analysis. PRKCQ-AS1 expression was modulated in NCI-H1395 cells via transfection. Cellular malignant phenotypes were assessed using CCK-8, Transwell, and flow cytometry assays. The regulatory effects on PD-1 and PD-L1 expression were confirmed by RT-qPCR and Western blotting. PRKCQ-AS1 was significantly downregulated in LUAD tissues and negatively correlated with advanced TNM stage and poor prognosis. Mechanistic analyses indicated that the ceRNA network involving PRKCQ-AS1 was strongly associated with immune-related pathways. Silencing of PRKCQAS1 markedly enhanced proliferation, migration, and invasion of LUAD cells while suppressing apoptosis in vitro. Notably, knockdown of PRKCQ-AS1 led to a significant upregulation of PD-1 and PD-L1 expression, suggesting that PRKCQ-AS1 inhibits immune escape by suppressing the PD-1/PD-L1 signaling axis. PRKCQ-AS1 acts as a potential tumor suppressor in LUAD. Its downregulation not only promotes tumor progression but also facilitates immune escape through dysregulation of the PD-1/PDL1 pathway. Therefore, PRKCQ-AS1 may serve as a promising biomarker for prognostic evaluation anda potential therapeutic target for immunotherapy in LUAD.  \nKeywords Lung adenocarcinoma, PRKCQ-AS1, Proliferation, Migration, Immune evasion  \nLung cancer remains the leading cause of cancer-related mortality globally, with lung adenocarcinoma (LUAD) representing the most common histological subtype of non-small cell lung cancer and accounting for 40% to 50% of all lung cancer cases1–3. Typically arising in the peripheral lung, LUAD often manifests as ground-glass nodules, exhibits inconspicuous early symptoms, and has a propensity for metastasis via the bloodstream or lymph nodes4,5. Although immune checkpoint inhibitors have demonstrated significant efficacy in treating malignant tumors such as melanoma6 and have become a focal point of oncology research, their overall impact on the five-year survival rate of patients with lung adenocarcinoma (LUAD) remains suboptimal. Furthermore, the high heterogeneity associated with these therapies contributes to considerable variability in prognosis among patients with similar clinical stages4,7 .  \nRecent studies suggest that the immunosuppressive nature of the tumor microenvironment and the development of chemotherapy resistance represent major obstacles to the effective treatment of malignant tumors. Evidence has increasingly highlighted the critical role of specific molecular markers in modulating the tumor  \n1Key Laboratory of Screening and Control of Infectious Diseases, Fujian Provincial University, Quanzhou Medical College, Quanzhou 362011, Fujian, China. 2Quanzhou Gaopin Medical Laboratory Co., Ltd., Quanzhou, Fujian, China. 3Meijie Wu and Yufang Wang have contributed equally to this work and shared first authorship. 􀀍 email:  \n[qmuliuben@163.com](qmuliuben@163.com); [lunyz@163.com](lunyz@163.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nimmune microenvironment and mediating therapeutic resistance. For instance, CAV1 has been demonstrated to promot","cbCaikux73G5ZtaW","https://ap.wps.com/l/cbCaikux73G5ZtaW","pdf",3915241,11,"English","# Introduction\n## Lung adenocarcinoma and immune checkpoint therapy\n## Tumor microenvironment, resistance, and long non-coding RNAs\n# Methods\n## Data sources and expression analysis (TCGA and specimens)\n## ceRNA network construction and functional assays\n# Results\n## PRKCQ-AS1 expression, TNM association, and prognosis\n## Effects on LUAD cell malignant phenotypes and apoptosis\n## Regulation of PD-1/PD-L1 via PRKCQ-AS1\n# Conclusion","[{\"question\":\"How was PRKCQ-AS1 expression and clinical significance evaluated in LUAD?\",\"answer\":\"PRKCQ-AS1 expression levels and clinical significance were analyzed using TCGA data and validated with clinical specimens. The results linked lower PRKCQ-AS1 to advanced TNM stage and poor prognosis.\"},{\"question\":\"What impact does PRKCQ-AS1 knockdown have on LUAD cell behaviors?\",\"answer\":\"Silencing PRKCQ-AS1 significantly enhanced proliferation, migration, and invasion of LUAD cells in vitro while suppressing apoptosis.\"},{\"question\":\"What mechanism connects PRKCQ-AS1 to immune escape in LUAD?\",\"answer\":\"PRKCQ-AS1 knockdown upregulated PD-1 and PD-L1 expression. The study indicates PRKCQ-AS1 inhibits immune escape by suppressing the PD-1/PD-L1 signaling axis.\"}]","Analysis of the mechanism and prognostic value of PRKCQ-AS1 in inhibiting the progression of lung adenocarcinoma via regulating the PD-1/PD-L1 pathway | PDF",1790100493,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63470e19098694fad8bda5aa0be1ba88.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15c457c09743d43a89d0127dc6339b8c.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d42262115c32e4521f8f9de1a6ca314.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8632b5738772578562de984c1c0b3c0.webp",980,1287]